Company Overview - Suzhou Zelgen Biopharmaceutical Co., Ltd. (Zelgen) has submitted a listing application to the Hong Kong Stock Exchange, with CICC as its sole sponsor [1] - Zelgen is a comprehensive biopharmaceutical company focused on the discovery, research and development, and commercialization of innovative small molecules and biologics, particularly in oncology, autoimmune diseases, and hemostasis/blood disorders [4] - Since its establishment in 2009, the company has developed a full-spectrum capability covering drug discovery, R&D, production, and commercialization, resulting in a diversified pipeline [4] Product Pipeline - Zelgen has three marketed drugs: - Zepubai® (Tolvaptan), the first domestically developed small molecule multi-target drug for first-line treatment of advanced liver cancer in China - Zepuping® (JAK inhibitor), the first domestically developed innovative JAK inhibitor for treating myelofibrosis - Zepuining® (recombinant human thrombin), the only recombinant human thrombin developed and commercialized using recombinant DNA technology in China [4] - The candidate drug pipeline includes 28 major clinical projects with 11 candidate drugs, of which 3 candidate drugs have 7 indications entering BLA/NDA or pivotal/Phase III clinical trial stages [4] Financial Performance - Revenue for the fiscal years 2022, 2023, 2024, and the nine months ending September 30, 2025, were RMB 301.67 million, RMB 383.56 million, RMB 531.53 million, and RMB 593.28 million respectively [6] - The company recorded losses of RMB 485.51 million, RMB 295.14 million, RMB 150.30 million, and RMB 95.60 million for the same periods [7] - Gross profit margins were 91.5%, 92.6%, 93.6%, and 89.8% for the respective years [8] Industry Overview - The global pharmaceutical market, including chemical drugs and biologics, is expected to reach USD 2.6493 trillion by 2035, with a compound annual growth rate (CAGR) of 5.1% from 2030 to 2035 [10] - In China, the pharmaceutical market is projected to grow faster than the global rate, reaching RMB 3.1034 trillion by 2035, with a CAGR of 7.8% [10] - China has seen a rapid increase in outbound licensing activities, with 94 transactions completed in 2024 totaling USD 51.9 billion, and 72 transactions in the first half of 2025 totaling USD 60 billion [10] - The global pharmaceutical transaction volume has decreased, but the total transaction value has increased from USD 177.5 billion in 2021 to USD 187.4 billion in 2024, indicating a strategic shift towards value-driven investments [10]

Company Overview - Suzhou Zelgen Biopharmaceutical Co., Ltd. (Zelgen) has submitted a listing application to the Hong Kong Stock Exchange, with CICC as its sole sponsor [1] - Zelgen is a comprehensive biopharmaceutical company focused on the discovery, research and development, and commercialization of innovative small molecules and biologics, particularly in oncology, autoimmune diseases, and hemostasis/blood disorders [4] - Since its establishment in 2009, the company has developed a full-spectrum capability covering drug discovery, R&D, production, and commercialization, resulting in a diversified pipeline [4] - Zelgen has three marketed drugs: Zepzelca® (donafenib tosylate tablets), the first domestically developed small molecule multi-target drug for first-line treatment of advanced liver cancer in China; Zepzelca® (gilteritinib tablets), the first domestically developed innovative JAK inhibitor for treating myelofibrosis; and Zepzhan® (recombinant human thrombin), the only recombinant human thrombin developed and commercialized using recombinant DNA technology in China [4] Financial Performance - For the fiscal years ending December 31, 2022, 2023, and projected for 2024 and 2025, the company reported revenues of RMB 301.67 million, RMB 383.56 million, RMB 531.53 million, and RMB 593.28 million respectively [6] - The cost of sales for the same periods was RMB 25.71 million, RMB 28.21 million, RMB 34.28 million, and RMB 60.24 million respectively [6] - Gross profit for the fiscal years was RMB 275.96 million, RMB 355.35 million, RMB 497.25 million, and RMB 533.04 million respectively, with corresponding gross profit margins of 91.5%, 92.6%, 93.6%, and 89.8% [6][8] - The company recorded losses of RMB 485.51 million, RMB 295.14 million, RMB 150.30 million, and RMB 95.60 million for the same periods [7] Industry Overview - The global pharmaceutical market, including chemical drugs and biologics, is expected to reach USD 2.6493 trillion by 2035, with a compound annual growth rate (CAGR) of 5.1% from 2030 to 2035 [10] - In China, the pharmaceutical market is projected to grow faster than the global rate, reaching RMB 3.1034 trillion by 2035, with a CAGR of 7.8% during the same period [10] - China has seen a rapid increase in outbound licensing activities, with 94 transactions completed in 2024, totaling USD 51.9 billion, and 72 transactions in the first half of 2025, totaling USD 60 billion [10] - Globally, while the volume of pharmaceutical transactions has declined, the total transaction value has continued to grow, indicating a strategic shift towards value-enhancing and quality-oriented investments [10]